周三盘中，生物制药公司Scholar Rock Holding Corp（SRRK）股价大幅下跌18.7%，引发投资者关注。此轮跌势主要由该公司发布的令人失望的季度财报所引发。
根据最新公布的财报，Scholar Rock截至6月30日的季度调整后每股亏损达0.98美元，远超分析师平均预期的0.66美元亏损。值得注意的是，这已经是该公司连续第四个季度未能达到盈利预期。公司当季净亏损高达1.103亿美元，而收入仍为零。
尽管Scholar Rock在生物技术和医学研究领域仍受到分析师的看好，平均评级维持"买入"，但此次业绩大幅低于预期显然打击了投资者信心。公司股价今年迄今已下跌14.4%，而此次财报无疑将进一步加剧市场对其财务状况的担忧。投资者将密切关注公司未来的研发进展和财务表现，以评估其长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.